Soliman et al. BMC Cancer (2020) 20:81
Hatem Soliman, Varsha Shah, Gordan Srkalovic, Reshma Mahtani, Ellis Levine, Blanche Mavromatis, Jayanthi Srinivasiah, Mohamad Kassar, Robert Gabordi, Rubina Qamar, Sarah Untch, Heather M. Kling, Tina Treece1, William Audeh
Results from the IMPACt trial measured changes in both treatment decisions and physician confidence when using the MammaPrint® and BluePrint® assays to support medical management for patients with early stage breast cancer.
Read more: Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer